Legend Biotech reports three-year follow-up data on Phase 3 CARTITUDE-4 study

Legend Biotech Corporation announced late-breaking three-year follow-up data from the Phase 3 CARTITUDE-4 study that shows a single infusion of CARVYKTI significantly extended overall survival in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor, and an immunomodulatory agent, reducing the risk of death by 45 percent versus standard therapies of pomalidomide, bortezomib and dexamethasone or daratumumab, pomalidomide and dexamethasone. CARVYKTI is now the first and only cell therapy to improve OS versus standard therapies for patients with lenalidomide-refractory multiple myeloma as early as second line. These results were presented as a late-breaking oral presentation at the 2024 International Myeloma Society Annual Meeting in Rio de Janeiro, Brazil. “These long-term results are groundbreaking and demonstrate that CARVYKTI significantly extends patients’ overall survival and meaningly improves their quality of life,” said Maria-Victoria Mateos, M.D., Ph.D., Consultant Physician in the Hematology Department and Associate Professor of Medicine at the University of Salamanca, Spain. “These data show that with a single infusion, we can reduce the risk of death and offer multiple myeloma patients the opportunity to live longer.”